Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 4:30 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 4:30 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Zacks News
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?
by Zacks Equity Research
In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.
Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
by Zacks Equity Research
ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?
by Zacks Equity Research
CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.
Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%
by Zacks Equity Research
Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.
What's in the Cards for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Marinus Stock Surges on Successful Phase II Epilepsy Study
by Zacks Equity Research
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
What's in Store for Adverum (ADVM) in Q1 Earnings?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.